Newsroom

All News
  • All News
  • In the News
  • Press Releases
  • Publications
  • Events
  • Noteworthy Articles
Infection Today (logo)

In the news: Septicyte RAPID test mentioned in Infection Control Today

From the article in Infection Control Today SeptiCyte RAPID test Sepsis is an overwhelming immune response to infection that can be life-threatening. Immunexpress’ SeptiCyte RAPID test is meant to ensure the timely and accurate diagnosis of sepsis, which is critical to allow clinicians to rapidly make correct treatment decisions that...
Cision PR Newswire

Immunexpress to Present Data at ECCMID 2023 Indicating that SeptiCyte® RAPID Differentiates Sepsis from Non-Sepsis in Patients with Uncertain Initial Diagnosis

This post originally appeared on Cision PR Newswire SEATTLE and BRISBANE, Australia, April 5, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today a poster presentation at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) which evaluates the use of SeptiCyte® RAPID...
MedTech Gurus

Rollie Carlson Ph. D podcast interview with Tom Hickey of Med Tech Gurus

Immunexpress - the signature diagnostics for sepsis

Immunexpress to Present Data at ISICEM 2023 Indicating that SeptiCyte® RAPID Outperforms Other Rapid Measures for Sepsis Diagnosis

360DX

Immunexpress Begins US Commercialization of Sepsis Diagnostic Test

Immunexpress - the signature diagnostics for sepsis

New Publication Validates SeptiCyte® RAPID as a Triaging Tool for COVID-19 Patients

SeptiCyte RAPID accurately assessed COVID-19 severity Elevated SeptiScore upon hospital intake was predictive of ICU admission SeptiCyte RAPID performed better than single-biomarker assays that are routinely used to assess COVID-19 severity SEATTLE and BRISBANE, Australia, Feb. 2, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving...
AMP 2020 Annual Meeting and Expo

At AMP 2022, Immunexpress launches rapid test for sepsis requiring two minutes hands-on time

From Leo O'Connor of LabPulse.com At the Association for Molecular Pathology annual meeting and exposition this week, Immunexpress launched a rapid molecular diagnostic test that could enable ruling in or ruling out sepsis in one hour. The SeptiCyte Rapid test is different from almost all other sepsis tests on the market by...
Cision PR Newswire

A multi-site study confirms the use of undiluted EDTA blood for the SeptiCyte RAPID sepsis assay

Data Validating EDTA Blood as Sample Type for SeptiCyte® RAPID Presented at the Association for Molecular Pathology 2022 Annual Meeting SEATTLE and BRISBANE, Australia, Nov. 3, 2022 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the presentation of an abstract at the Association for...
Screenshot from ContagionLive interview with Dr. Roy Davis

ContagionLive interview: A Rapid Sepsis Diagnostic Test for Better Patient Outcomes

Nina Cosdon of ContagionLive interviewed the chief medical officer of Immunexpress Inc., Roy Davis, MD, PhD, MHA, in a post titled A Rapid Sepsis Diagnostic Test for Better Patient Outcomes. Sepsis diagnosis often takes days. Dr. Roy Davis and his team have developed a test that can diagnose sepsis in...
Immunexpress - the signature diagnostics for sepsis

CEO Rolland Carlson: When Advancing a Medical Device, Be A Partner First & Seller Second to Hospital Systems

Immunexpress CEO Rolland Carlson was recently featured on HITConsultant, which provides healthcare technology news, analysis and insights for healthcare executives, physicians and providers. "US hospital systems validate the safety, clinical utility, and robustness of newly FDA-approved devices, 510(k) cleared, before adopting them into clinical practice. This work occurs alongside evaluating...
Dr. Rollie Carlson was interviewed for Docwire News

Interview with DocWireNew: Dr. Rollie Carlson, CEO, Immunexpress: Providing RAPID Detection for Sepsis

DocWire News spoke with Dr. Rollie Carlson, CEO of Immunexpress, to learn more about this cutting-edge technology, and how it can quickly and accurately detect sepsis, and lead to faster treatment. https://youtu.be/Vd0FL3fYPwY
Drug Target Review screenshot

Interview with Dr Rolland Carlson and Dr Richard Brandon

Download the Drug Target Review interview with Dr. Rolland Carlson and Dr. Richard Brandon.(pdf) The 2022 Drug Target Review Assays ebook, includes an interview about our sepsis detection initiative. In this collection of articles, Dr. Rolland Carlson and Dr. Richard Brandon, Immunexpress, answer questions about molecular...

If you are a member of the media, please contact:

Scott Stachowiak
Russo Partners
(646) 942-5630
scott.stachowiak@russopartnersllc.com